Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...

The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing surgery alone to neoadjuvant chemotherapy with or without immunotherapy.

The 24-month metastasis-free survival rate was 75.1% in the durvalumab arm and 65.1% in the control arm. Perioperative durvalumab improves upon neoadjuvant chemotherapy in patients with ...

Neoadjuvant Opdivo with chemotherapy significantly improves overall survival in resectable NSCLC compared to chemotherapy alone, as shown in the CheckMate-816 study. The study's primary endpoints, ...

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

Neoadjuvant chemotherapy with a regimen of gemcitabine-cisplatin for high-risk upper tract urothelial carcinoma (UTUC) resulted in a high rate of downstaging, and should now be considered a new ...

We would like to comment on Schuler et al., on their well-designed randomized phase II NEOpredict-Lung study (NCT04205552) which was published in Nature Medicine. The main objective of this study was ...

Nonresponders to UTUC neoadjuvant chemo have more aggressive recurrence patterns that may have important surveillance and treatment implications. Patients with node-positive disease after neoadjuvant ...

The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...